Sutro Biopharma (STRO) Total Current Liabilities (2017 - 2025)

Sutro Biopharma has disclosed Total Current Liabilities across 9 years of filings, most recently posting $75.1 million for Q4 2025.

• Total Current Liabilities for Q4 2025 came in at $75.1 million, down 43.03% year-over-year; the trailing twelve-month figure through Dec 2025 was $75.1 million (down 43.03% YoY), and the FY2025 annual result was $75.1 million, down 43.03% from the prior year.
• Total Current Liabilities came in at $75.1 million for Q4 2025 at Sutro Biopharma, up from $71.9 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $133.0 million in Q1 2025 to a low of $22.7 million in Q1 2021.
• The 5-year median for Total Current Liabilities is $69.5 million (2023), against an average of $72.8 million.
• Across the five-year window, Total Current Liabilities jumped 93.65% in 2024 and tumbled 45.24% in 2025, its largest moves.
• Sutro Biopharma's Total Current Liabilities stood at $41.7 million in 2021, then surged by 59.45% to $66.5 million in 2022, then soared by 40.87% to $93.7 million in 2023, then jumped by 40.69% to $131.9 million in 2024, then slumped by 43.03% to $75.1 million in 2025.
• The last three Total Current Liabilities figures came in at $75.1 million (Q4 2025), $71.9 million (Q3 2025), and $74.2 million (Q2 2025), per Business Quant data.